Icariside II facilitates the differentiation of ADSCs to schwann cells and restores erectile dysfunction through regulation of miR-33/GDNF axis

Zheng, Tao; Zhang, Tianbiao; Zhang, Weixing; Lv, Kun-Long; Jia, Dawei; Yang, Fan; Sun, Yangyang; Lian, Jingyao; Wang, Rui

doi:10.1016/j.biopha.2020.109888

Cited by 17 publications

(15 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ever since the ancient Chinese era, Epimedium extract has been widely used as an aphrodisiac. In the past few years, many studies have investigated and proved the role of icariin and icariside II in the treatment of erectile dysfunction [ 34 ]. An improvement in erectile function was observed in spontaneously hypertensive rats, since icariin successfully decreased the content of endothelial microparticles in their blood, from 1.58% in the control group to 1.01% [ 35 ].…”

Section: Icariin and Its Derivatesmentioning

confidence: 99%

Bioavailability Improvement Strategies for Icariin and Its Derivates: A Review

Szabó

Rácz

Dulf

2022

IJMS

View full text Add to dashboard Cite

In recent years, there has been considerable interest in icariin (ICA) and its derivates, icariside II (ICS) and icaritin (ICT), due to their wide range of potential applications in preventing cancer, cardiovascular disease, osteoporosis, delaying the effects of Alzheimer’s disease, treating erectile dysfunction, etc. However, their poor water solubility and membrane permeability, resulting in low bioavailability, dampens their potential beneficial effects. In this regard, several strategies have been developed, such as pharmaceutical technologies, structural transformations, and absorption enhancers. All these strategies manage to improve the bioavailability of the above-mentioned flavonoids, thus increasing their concentration in the desired places. This paper focuses on gathering the latest knowledge on strategies to improve bioavailability for enhancing the efficacy of icariin, icariside II, and icaritin. We conclude that there is an opportunity for many further improvements in this field. To the best of our knowledge, no such review articles scoping the bioavailability improvement of icariin and its derivates have been published to date. Therefore, this paper can be a good starting point for all those who want to deepen their understanding of the field.

show abstract

Section: Icariin and Its Derivatesmentioning

confidence: 99%

Bioavailability Improvement Strategies for Icariin and Its Derivates: A Review

Szabó

Rácz

Dulf

2022

IJMS

View full text Add to dashboard Cite

show abstract

“…The underlying mechanism is possibly involved in regulating microRNA-33 which negatively activated glial cell-derived neurotrophic factor and its p75 neurotrophic receptor. 206 The administration of Hongjing I granules (a new herbal formula derived from traditional Chinese medicine) improved ED in CNI rats dose-dependent. Furthermore, this herbal treatment increased nNOS expression, Schwann cells viability and promoted neurites regeneration of major pelvic ganglia.…”

Section: Galaninmentioning

confidence: 99%

“…Recently, a flavonol isolated from the stems and leaves of herbs epimedii, icariside II, induced the differentiation of ADSCs to Schwann cells and recovered EF of BCNI rats. The underlying mechanism is possibly involved in regulating microRNA‐33 which negatively activated glial cell‐derived neurotrophic factor and its p75 neurotrophic receptor 206 …”

Section: Introductionmentioning

confidence: 99%

An update on the current status and future prospects of erectile dysfunction following radical prostatectomy

Asker

Yilmaz‐Oral

Öztekin³

et al. 2022

The Prostate

View full text Add to dashboard Cite

Background: Radical prostatectomy (RP) and radiation treatment are standard options for localized prostate cancer. Even though nerve-sparing techniques have been increasingly utilized in RP, erectile dysfunction (ED) due to neuropraxia remains a frequent complication. Erectile function recovery rates after RP remain unsatisfactory, and many men still suffer despite the availability of various therapies. Objective: This systematic review aims to summarize the current treatments for post-RP-ED, assess the underlying pathological mechanisms, and emphasize promising therapeutic strategies based on the evidence from basic research. Method: Evaluation and review of articles on the relevant topic published between 2010 and 2021, which are indexed and listed in the PubMed database. Results: Phosphodiesterase type 5 inhibitors, intracavernosal and intraurethral injections, vacuum erection devices, pelvic muscle training, and surgical procedures are utilized for penile rehabilitation. Clinical trials evaluating the efficacy of erectogenic drugs in this setting are conflicting and far from being conclusive. The use of androgen deprivation therapy in certain scenarios after RP further exacerbates the already problematic situation and emphasizes the need for effective treatment strategies. Conclusion: This article is a detailed overview focusing on the pathophysiology and mechanism of the nerve injury developed during RP and a compilation of various strategies to induce cavernous nerve regeneration to improve erectile function (EF). These strategies include stem cell therapy, gene therapy, growth factors, lowintensity extracorporeal shockwave therapy, immunophilins, and various pharmacological approaches that have induced improvements in EF in experimental models of cavernous nerve injury. Many of the mentioned strategies can improve EF following RP if transformed into clinically applicable safe, and effective techniques with reproducible outcomes.

show abstract

“…Further research on growth factors released by the stem cells may be able to compensate for the lack of mechanism description to some extent. Zheng et al [ 83 ] conducted a more detailed study and partially explained the mechanism. ASCs were pretreated with icariside II for differentiation into Schwann cells and then were used to treat ED caused by nerve injury.…”

Section: Advances In Ascs Therapy For the Lower Urinary Tractmentioning

confidence: 99%

Therapies Based on Adipose-Derived Stem Cells for Lower Urinary Tract Dysfunction: A Narrative Review

et al. 2022

View full text Add to dashboard Cite

Lower urinary tract dysfunction often requires tissue repair or replacement to restore physiological functions. Current clinical treatments involving autologous tissues or synthetic materials inevitably bring in situ complications and immune rejection. Advances in therapies using stem cells offer new insights into treating lower urinary tract dysfunction. One of the most frequently used stem cell sources is adipose tissue because of its easy access, abundant source, low risk of severe complications, and lack of ethical issues. The regenerative capabilities of adipose-derived stem cells (ASCs) in vivo are primarily orchestrated by their paracrine activities, strong regenerative potential, multi-differentiation potential, and cell–matrix interactions. Moreover, biomaterial scaffolds conjugated with ASCs result in an extremely effective tissue engineering modality for replacing or repairing diseased or damaged tissues. Thus, ASC-based therapy holds promise as having a tremendous impact on reconstructive urology of the lower urinary tract.

show abstract

Icariside II facilitates the differentiation of ADSCs to schwann cells and restores erectile dysfunction through regulation of miR-33/GDNF axis

Cited by 17 publications

References 26 publications

Bioavailability Improvement Strategies for Icariin and Its Derivates: A Review

Bioavailability Improvement Strategies for Icariin and Its Derivates: A Review

An update on the current status and future prospects of erectile dysfunction following radical prostatectomy

Therapies Based on Adipose-Derived Stem Cells for Lower Urinary Tract Dysfunction: A Narrative Review

Contact Info

Product

Resources

About